Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Lucjan, Wyrwicz"'
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Jean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, Michael J. Seckl, Jourik Gietema, Wouter W. de Herder, Martyn Caplin, Heinz-Josef Klümpen, Olivier Glehen, Lucjan Wyrwicz, Robin Peeters, Lisa Licitra, Nicolas Girard, Sophie Piperno-Neumann, Ellen Kapiteijn, Ahmed Idbaih, Enrico Franceschi, Annalisa Trama, Anna-Maria Frezza, Peter Hohenberger, Nadia Hindi, Javier Martin-Broto, Johanna Schell, Muriel Rogasik, Stephane Lejeune, Kathy Oliver, Francesco de Lorenzo, Ariane Weinman
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100861- (2024)
Summary: About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality o
Externí odkaz:
https://doaj.org/article/4f20025ebba2481ba272e65734dc8627
Autor:
Maria Kulecka, Paweł Czarnowski, Aneta Bałabas, Maryla Turkot, Kamila Kruczkowska-Tarantowicz, Natalia Żeber-Lubecka, Michalina Dąbrowska, Ewa Paszkiewicz-Kozik, Jan Walewski, Iwona Ługowska, Hanna Koseła-Paterczyk, Piotr Rutkowski, Anna Kluska, Magdalena Piątkowska, Agnieszka Jagiełło-Gruszfeld, Michał Tenderenda, Cieszymierz Gawiński, Lucjan Wyrwicz, Magdalena Borucka, Maciej Krzakowski, Leszek Zając, Michał Kamiński, Michał Mikula, Jerzy Ostrowski
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 15, p 8026 (2024)
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to identify common and distinc
Externí odkaz:
https://doaj.org/article/30b6864b982d48a4bee47b7dc00ebf5c
Autor:
Agnieszka Durbajło, Marcin Świeżyński, Beata Ziemba, Danuta Starzyczny-Słota, Marzena Samborska-Plewicka, Anna Cencelewicz-Lesikow, Agata Chrzanowska-Kapica, Aneta Dobrzyńska-Rutkowska, Iwona Drab-Mazur, Monika Kulma-Kreft, Magdalena Sikora-Skrabaka, Elwira Matuszewska, Małgorzata Foszczyńska-Kłoda, Tomasz Lewandowski, Grzegorz Słomian, Krystyna Ostrowska-Cichocka, Ewa Chmielowska, Rafał Wiśniowski, Anna Twardosz, Katarzyna Wierzbicka, Leszek Rumianowski, Lucjan Wyrwicz
Publikováno v:
Cancers, Vol 16, Iss 11, p 1992 (2024)
Background: This was an observational study prospectively evaluating the effectiveness and safety of aflibercept/FOLFIRI administered in second-line mCRC per the reimbursement criteria in Poland. Methods: Consecutive mCRC patients who progressed with
Externí odkaz:
https://doaj.org/article/b23d033a61464704a12ea7df04ccf99a
Autor:
Julien Taieb, Timothy Price, Loïck Vidot, Bénédicte Chevallier, Lucjan Wyrwicz, Jean-Baptiste Bachet
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background PRECONNECT was an international, phase IIIb trial evaluating the safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer (mCRC). Methods Patients with mCRC received FTD/TPI 35 mg/m2 twice-daily on
Externí odkaz:
https://doaj.org/article/c29a504b030d4e2fb5ded3f0ac9c5e4b
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 545-558 (2022)
Rectal cancer constitutes around one-third of all colorectal cancers. New markers are required to optimize the treatment. Extramural vascular invasion (EMVI) is a magnetic resonance imaging (MRI)-based negative prognostic marker. Lymphocyte-to-monocy
Externí odkaz:
https://doaj.org/article/b9f5988bd09d47cba2491aa0bc93fc93
Autor:
Cieszymierz Gawiński, Andrzej Mróz, Katarzyna Roszkowska-Purska, Iwona Sosnowska, Edyta Derezińska-Wołek, Wojciech Michalski, Lucjan Wyrwicz
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 3048 (2023)
Rectal cancer constitutes over one-third of all colorectal cancers (CRCs) and is one of the leading causes of cancer-related deaths in developed countries. In order to identify high-risk patients and better adjust therapies, new markers are needed. S
Externí odkaz:
https://doaj.org/article/3b8355758bb547a6b5babfccf96dd4e1
Autor:
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero
Publikováno v:
New England Journal of Medicine. 388:1657-1667
Autor:
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Chen-Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H Yoon
Publikováno v:
The Lancet Oncology. 24:483-495
Autor:
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract Background We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC
Externí odkaz:
https://doaj.org/article/22a26bd6feb14e4185d7a995dfe688b6